60 Degrees Pharmaceuticals strikes warrant inducement deal with existing holders
The company agreed to reprice existing warrants to $0.90 and issue new warrants for 200% more shares to raise roughly $526,000 before fees.
SEC filing
4 stories
The company agreed to reprice existing warrants to $0.90 and issue new warrants for 200% more shares to raise roughly $526,000 before fees.
SEC filing
The filing details a 30-patient hospital study, a chronic-disease trial, and plans for a possible sNDA filing in 2027 with a requested priority review.
SEC filing
The company's October 6 webinar detailed an interim DSMB recommendation to complete its 33-subject hospital study as planned, with unblinding expected in early January 2027.
SEC filing
The company asked for a Commissioner's National Priority Voucher to speed review of tafenoquine for babesiosis, with a DSMB analysis due October 1, 2026.
SEC filing